Xavier Flinois - PAREXEL International President - Perceptive Informatics

Mr. Xavier AB Flinois is President PAREXEL Informatics of Parexel International Corporationrationration. From September 2009 to June 2012, he served as the Chief Executive Officer of Clinical Solutions, a supplier of clinical software solutions to the healthcare industry. From January 2007 to September 2009, he served as General Partner of Houat Partners, a consulting and investment firm. Prior to this, he served as the Chief Executive Officer of SchlumbergerSema, an international IT services company. Xavier holds a Masters degree in Science from cole Polytechnique and a Masters degree in Engineering from cole des Ponts et Chausses.
Age: 53  President Since 2015      
781 487-9900  http://www.parexel.com

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Catherine KnuppZoetis
John GrayVertex Pharmaceuticals Incorpor
Charles MilsteinVertex Pharmaceuticals Incorpor
Roxanne LaganoZoetis
Douglas McCorkleRegeneron Pharmaceuticals
Svend AndersenPerrigo Company Plc
Louis YuPerrigo Company Plc
Grainne QuinnPerrigo Company Plc
Samiran DasDr Reddys Laboratories Ltd
Alok SonigDr Reddys Laboratories Ltd
Thomas FarringtonPerrigo Company Plc
Kristin PeckZoetis
Christopher FenimoreRegeneron Pharmaceuticals
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
Charles WagnerVertex Pharmaceuticals Incorpor
Jeffrey NeedhamPerrigo Company Plc
Umang VohraDr Reddys Laboratories Ltd
Clinton LewisZoetis
George YancopoulosRegeneron Pharmaceuticals
Peter PowchikRegeneron Pharmaceuticals
Ian SmithVertex Pharmaceuticals Incorpor

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 200 shares of
a day ago
Traded for 14.76
Purchased over 50 shares of
a day ago
Traded for 53.37
Purchased few shares of
a day ago
Traded for 270.71
Purchased over 40 shares of
a day ago
Traded for 75.81
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.
Search macroaxis.com